Search results
US FDA panel votes against first MDMA-based PTSD treatment
Colorado Springs Gazette· 2 days agoThe panel voted 10-to-1 against the first MDMA-based PTSD treatment, saying the benefits did not...
Kaya Holdings, Inc. "The Sacred Mushroom" Psilocybin Treatment Center Begins Accepting Appointments
Morningstar· 1 day agoThe Sacred Mushroom™ has been purposely designed to provide all TSM guests with the opportunity to fully experience the transformative potential of the psychedelic journey.
FDA Panel Says No to MDMA as Treatment for PTSD | Fox 11 Tri Cities Fox 41 Yakima
FOX 11/41 Yakima· 1 day ago“It seems like there are so many problems with the data — each one alone might be OK, but when you...
FDA Panel Says No to MDMA as Treatment for PTSD
KLAX-TV· 1 day ago“It seems like there are so many problems with the data -- each one alone might be OK, but when you pile them on top of each other … there’s just a lot...
U.S. health experts vote against MDMA as treatment for PTSD
The Raw Story· 1 day agoA panel of U.S. health experts convened by the Food and Drug Administration on Tuesday...
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
WTVG 13 Action News· 2 days agoA first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was...
FDA Staff Questions Safety of MDMA Treatment for PTSD
MedPage Today· 7 days agoIf eventually approved by the agency, Lykos Therapeutics' MDMA could become a first-in-class ...
FDA Panel Rejects MDMA-Assisted Therapy For PTSD
Forbes· 1 day agoAfter listening to public comments and a discussion period, the FDA’s independent Psychopharmacologic Drugs Advisory Committee voted 9-2 against...
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
Eyewitness News 3 Hartford· 2 days agoA first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was...
FDA advisors reject MDMA therapy for PTSD, amid concerns over research
MPR News· 1 day agoIt represents a major setback for proponents of the drug and its sponsor Lykos Therapeutics, potentially jeopardizing FDA approval of the treatment. Following public comment ...